伤害在哪里?内分泌与代谢疾病靶向治疗临床试验中不良事件报告不足:一项观察性研究
该研究评估了内分泌与代谢疾病靶向治疗临床试验在ClinicalTrials.gov注册库与同行评议期刊中不良事件报告的完整性与一致性。在92项符合纳入标准的试验中,注册库全部报告了严重不良事件、其他不良事件和全因死亡率数据,而期刊报告率分别为86%、91%和64%,且两来源间不良事件报告存在显著差异。
要点
- 注册库中全部试验报告了严重不良事件、其他不良事件及全因死亡率数据。
- 期刊中严重不良事件报告率为86%,其他不良事件为91%,全因死亡率为64%。
- 两来源均报告时,38%的试验严重不良事件例数不一致,其他不良事件86%不一致,全因死亡率36%不一致。
核心结论
- 分析显示,内分泌与代谢疾病靶向治疗临床试验的注册库数据与期刊文章在不良事件报告方面存在显著差异,需要加强透明度与报告一致性。
研究设计与样本
- 2022年9月12日检索ClinicalTrials.gov,纳入2009年9月1日后注册、已完成的内分泌与代谢疾病靶向治疗干预性试验,最终92项符合标准。
- 主要结局为注册库与对应期刊文章中不良事件报告的完整性,并评估严重不良事件、其他不良事件及主要完成日期在2017年1月18日之后试验的全因死亡率数据,同时检查两来源报告的一致性。
主要发现
- 注册库中全部92项试验均报告了严重不良事件和其他不良事件,所有符合条件试验均报告了全因死亡率数据。
- 期刊文章中,86%的试验报告了严重不良事件,91%报告了其他不良事件,64%报告了全因死亡率数据。
- 在注册库与期刊均完整报告不良事件的试验中,38%的试验严重不良事件经历例数存在差异,其他不良事件为86%,全因死亡率数据为36%。
- 18%的期刊文章使用了与注册库不同的不良事件术语,60%应用了不同的频率阈值。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: This study aimed to assess the completeness and consistency of adverse event (AE) reporting in ClinicalTrials.gov and corresponding peer-reviewed publications for clinical trials investigating targeted therapeutics for endocrine and metabolic disorders. STUDY DESIGN AND SETTING: On September 12, 2022, a search of ClinicalTrials.gov was conducted to identify completed interventional trials investigating targeted therapeutics for the treatment of endocrine and metabolic disorders registered after September 1, 2009. The main outcome was the completeness of AE reporting in ClinicalTrials.gov and corresponding peer-reviewed journal articles. The completeness of registry reporting for serious AEs (SAEs) and other AEs (OAEs) was also assessed, as well as the all-cause mortality (ACM) data for trials with a primary completion date after January 18, 2017. In addition, the study examined the concordance in AE reporting between the two sources. RESULTS: Out of 7405 trials identified in the ClinicalTrials.gov registry, 92 met the inclusion criteria. All trials reported SAEs and OAEs in the registry, and all eligible trials reported ACM data. In the corresponding peer-reviewed journal publications, SAEs were reported for 86% of trials, OAEs for 91%, and ACM data for 64% of eligible trials. Among the trials with complete AE reporting in ClinicalTrials.gov and journal publications, 38% showed discrepancies in the number of participants experiencing SAEs, 86% for OAEs, and 36% for ACM data. In addition, 18% of journal articles used different terminology for reporting of AEs compared to the registry, and 60% applied different frequency thresholds. CONCLUSION: Our analysis revealed significant discrepancies between registry data and journal articles regarding AE reporting in clinical trials investigating targeted therapy for endocrine and metabolic disorders. Greater efforts are needed to enhance transparency and harmonization in AE reporting, ensuring accurate risk communication and informed clinical decision-making. PLAIN LANGUAGE SUMMARY: Accurate reporting of adverse events (AEs) in clinical trials is essential for evaluating the safety of new therapeutics. This study assessed whether safety data reported in clinical trials investigating treatments for endocrine and metabolic disorders were consistently presented in ClinicalTrials.gov and corresponding journal publications. A total of 92 completed clinical trials registered on ClinicalTrials.gov and their published articles were analyzed. Although all trials reported serious AEs (SAEs), other AEs (OAEs), and mortality data in the registry, journal publications frequently omitted these data. Specifically, 86% of journal articles reported SAEs, 91% reported OAEs, and only 64% provided data on mortality. Even when AEs were reported in both sources, inconsistencies were common. Differences in the number of participants experiencing AEs were found in 38% of trials for SAEs, 86% for OAEs, and 36% for mortality data. In addition, 18% of journal articles used different terminology, and 60% applied different thresholds for reporting AEs compared to the registry. These findings underscore substantial inconsistencies between clinical trial registry data and peer-reviewed publications, highlighting the need for improved reporting practices. Greater transparency and standardization in AE reporting are essential to ensure the reliability of safety data for novel therapeutics.
引用
- Pavić M, Pranić S, Marušić A, et al. Where are the harms? Underreporting of adverse events in clinical trials investigating targeted therapy for endocrine and metabolic disorders: an observational study. J Clin Epidemiol. 2025. PMID: 40484292. doi:10.1016/j.jclinepi.2025.111861
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。